Association of XRCC3 rs1799794 polymorphism with survival of glioblastoma multiforme patients treated with combined radio-chemotherapy

被引：4

作者：

Pasqualetti, Francesco ^{[1
]}

Gonnelli, Alessandra ^{[1
]}

Orlandi, Paola ^{[2
]}

Palladino, Eleonora ^{[1
]}

Giannini, Noemi ^{[1
]}

Gadducci, Giovanni ^{[1
]}

Mattioni, Roberto ^{[1
]}

Montrone, Sabrina ^{[1
]}

Calistri, Elisa ^{[1
]}

Mazzanti, Chiara Maria ^{[3
]}

Franceschi, Sara ^{[3
]}

Ortenzi, Valerio ^{[4
]}

Scatena, Cristian ^{[3
]}

Zavaglia, Katia ^{[5
]}

Fanelli, Giuseppe Nicolo ^{[4
]}

Morganti, Riccardo ^{[6
]}

Santonocito, Orazio ^{[7
]}

Bocci, Guido ^{[2
]}

Naccarato, Giuseppe Antonio ^{[4
]}

Paiar, Fabiola ^{[1
]}

机构：

[1] Pisa Univ Hosp, Radiat Oncol Unit, Via Roma 67, I-56123 Pisa, Italy

[2] Univ Pisa, Dept Clin & Expt Med, I-56126 Pisa, Italy

[3] Fdn Pisana Sci, Lab Genom & Transcript, Pisa, Italy

[4] Univ Pisa, Dept Translat Res & New Technol Med & Surg, I-56100 Pisa, Italy

[5] Pisa Univ Hosp, Dept Lab Med, Div Mol Genet, Pisa, Italy

[6] Univ Pisana, Pisa Univ Hosp, Sect Stat, Azienda Osped, Pisa, Italy

[7] Livorno Gen Hosp, Area Vasta NordOvest, Nurosurg Unit, Livorno, Italy

来源：

INVESTIGATIONAL NEW DRUGS | 2021年 / 39卷 / 04期

关键词：

Single nucleotide polymorphism; Pharmacogenetic; Translational research; Glioblastoma; Radiotherapy biomarkers;

D O I：

10.1007/s10637-021-01075-9

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

This study reports the results of a monocentric prospective analysis conducted with the aim of evaluating the impact of XRCC1 rs25487, XRCC3 rs861539, XRCC3 rs1799794, RAD51 rs1801320 and GSTP-1 rs1695 single nucleotide polymorphisms (SNP) on patients with high-grade glioma treated with concomitant radio-chemotherapy. From October 2010 to August 2019, a total of 75 patients aged >= 18 years, with histological diagnosis of high-grade glioma, isocitrate dehydrogenase (IDH) 1/2 wild type and treated with radio-chemotherapy and sequential chemotherapy with temozolomide (TMZ) were prospectively recruited. The local ethic committee approved this study (Comitato Etico di Area Vasta Nord Ovest [CEAVNO]; protocol 3304/2011). After a median follow up of 25 months (range: 7-98 months), median progression-free survival (PFS) and overall survival (OS) were 11 months (CI95%: 8-14 months) and 18 months (CI95%: 15-21 months), respectively. In univariate and multivariate Cox regression analysis, a statistically significant association with PFS and OS was found with XRCC3 rs1799794 SNP. The study suggests that XRCC3 rs1799794 SNP can be associated with different PFS and OS in glioblastoma patients treated with radio-chemotherapy.

引用

页码：1159 / 1165

页数：7

共 50 条

[31] THE PLASTICITY AND SURVIVAL OF GLIOBLASTOMA STEM CELLS DEPEND ON GD3, WHOSE INHIBITION IS SYNERGISTIC WITH RADIO-CHEMOTHERAPY
Hein, V.
Baeza-Kallee, N.
Berges, R.
Appay, R.
Snacel-Fazy, E.
Tchoghandjian, A.
Figarella-Branger, D.
Tabouret, E.
[J]. NEURO-ONCOLOGY, 2023, 25
[32] Association between XRCC3 rs861539 Polymorphism and the Risk of Ovarian Cancer: Meta-Analysis and Trial Sequential Analysis
Hu, Siya
Jing, Yunnan
Liu, Fangyuan
Han, Fengjuan
[J]. BIOMED RESEARCH INTERNATIONAL, 2022, 2022
[33] Promising survival for patients with glioblastoma multiforme treated with individualised chemotherapy based on in vitro drug sensitivity testing
Iwadate, Y
Fujimoto, S
Namba, H
Yamaura, A
[J]. BRITISH JOURNAL OF CANCER, 2003, 89 (10) : 1896 - 1900
[34] Promising survival for patients with glioblastoma multiforme treated with individualised chemotherapy based on in vitro drug sensitivity testing
Y Iwadate
S Fujimoto
H Namba
A Yamaura
[J]. British Journal of Cancer, 2003, 89 : 1896 - 1900
[35] Comprehensive assessment of the association between DNA repair gene XRCC3 rs861539 C/T polymorphism and lung cancer risk
Ding, Gang
Xu, Weiguo
Hua, Hongwei
Huang, Qian
Liang, Hongxiang
Ni, Yufeng
Ding, Zhaoheng
[J]. TUMOR BIOLOGY, 2013, 34 (05) : 2521 - 2527
[36] Association between Rad-51 levels and survival in patients with glioblastoma multiforme treated with radiation therapy
Kumar, R.
Welsh, J.
Nagle, R. B.
Green, S.
Stea, B.
[J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2007, 69 (03): : S63 - S64
[37] Prognostic Value of Hemoglobin Concentrations in Patients with Advanced Head and Neck Cancer Treated with Combined Radio-Chemotherapy and Surgery
Wolfgang Wagner
Robert Hermann
Joachim Hartlapp
Elmar Esser
Bernhard Christoph
Michael Karl Müller
Rainer Krech
Olaf Koch
[J]. Strahlentherapie und Onkologie, 2000, 176 : 73 - 80
[38] Prognostic value of hemoglobin concentrations in patients with advanced head and neck cancer treated with combined radio-chemotherapy and surgery
Wagner, W
Hermann, R
Hartlapp, J
Esser, E
Christoph, B
Müller, MK
Krech, R
Koch, O
[J]. STRAHLENTHERAPIE UND ONKOLOGIE, 2000, 176 (02) : 73 - 80
[39] Association of XRCC3 and XPD751 SNP with efficacy of platinum-based chemotherapy in advanced NSCLC patients
Chen, Xiaoxia
Sun, Hui
Ren, Shengxiang
Curran, Vikramsingh Kim
Zhang, Ling
Zhou, Songwen
Zhang, Jie
Zhou, Caicun
[J]. CLINICAL & TRANSLATIONAL ONCOLOGY, 2012, 14 (03): : 207 - 213
[40] ASSOCIATION OF XRCC3 AND XPD751 SNP WITH RESPONSE TO PLATINUM-BASED CHEMOTHERAPY IN ADVANCED NSCLC PATIENTS
Chen, Xia X.
Sun, Hui
Ren, Xiang S.
Zhang, Ling
Zhou, Songwen
Zhou, Caicun
[J]. JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S1190 - S1190

← 1 2 3 4 5 →